Brought to you by 
Pfenex grants protein production rights to Merck
Jan 2010
Executive Summary
Protein production company Pfenex has granted Merck exclusive worldwide rights to its Pfenex Expression Technology for use in the development of a new undisclosed vaccine.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- In Vitro Diagnostics
-
Pharmaceuticals
- Vaccines
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfenex grants protein production rights to Merck
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice